02256.HK
Abbisko Cayman Limited
HKSE · Healthcare · Biotechnology · CN
HKD 6.19
−2.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 97.3M | 596.3M | 504.0M | 19.1M | — |
| Cost of Revenue | 1.8M | — | — | — | — |
| Gross Profit | 95.5M | 596.3M | 504.0M | 19.1M | — |
| Operating Expenses | |||||
| R&D Expense | 526.6M | 495.3M | 451.4M | 433.7M | 378.7M |
| SG&A Expense | 87.0M | 73.8M | 74.2M | 35.6M | 29.8M |
| General & Admin Expense | 87.0M | — | 74.2M | 35.6M | 29.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | 60.8M | 88.6M |
| Total Operating Expenses | 613.6M | 569.1M | 525.6M | 530.1M | 497.2M |
| Cost and Expenses | 615.4M | 569.1M | 525.6M | 530.1M | 497.2M |
| Operating Income (EBIT) | (518.1M) | 27.2M | (21.6M) | (511.1M) | (497.2M) |
| Non-Operating | |||||
| Interest Income | — | 90.5M | 89.1M | 65.5M | 35.0M |
| Interest Expense | — | 3.2M | 1.6M | 2.2M | 2.7M |
| Net Interest Income | 82.5M | 87.3M | 87.5M | 63.3M | 32.3M |
| Other Non-Op Income/Expense | 60.7M | 86.3M | 99.6M | 79.5M | 1.6M |
| Non-Operating Income (excl Interest) | — | — | — | (81.7M) | — |
| EBT (Pre-Tax Income) | (457.4M) | 113.4M | 78.0M | (431.6M) | (495.6M) |
| Income Tax Expense | 9.3M | 59.6M | 49.7M | — | 2.7M |
| Bottom Line | |||||
| Net Income | (466.7M) | 53.8M | 28.3M | (431.6M) | (498.3M) |
| Earnings from Cont. Ops | (466.7M) | 53.8M | 28.3M | (431.6M) | (495.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (466.7M) | 53.8M | 28.3M | (431.6M) | (495.6M) |
| Per Share | |||||
| Basic EPS | (HK$0.74) | HK$0.09 | HK$0.04 | (HK$0.67) | (HK$0.80) |
| Diluted EPS | (HK$0.74) | HK$0.08 | HK$0.04 | (HK$0.67) | (HK$0.80) |
| Revenue Per Share | HK$0.15 | HK$0.95 | HK$0.78 | HK$0.03 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 631.1M | 624.7M | 649.6M | 647.2M | 620.7M |
| Diluted Shares Outstanding | 631.1M | 639.8M | 649.6M | 647.2M | 620.7M |
| Profitability Metrics | |||||
| EBITDA | (502.3M) | 49.5M | 2.0M | (411.0M) | (481.4M) |
| D&A | 15.8M | 22.3M | 23.6M | 18.4M | 15.8M |
| EBIT | (518.1M) | 27.2M | (21.6M) | (429.4M) | (497.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026